| Recruiting | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABR NCT07172958 | Children's National Research Institute | Phase 1 |
| Recruiting | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-speci NCT07148050 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells NCT06198296 | Baylor College of Medicine | Phase 1 |
| Not Yet Recruiting | Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models NCT06822842 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatri NCT04715191 | Baylor College of Medicine | Phase 1 |
| Recruiting | A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared NCT05735977 | Birmingham Women's and Children's NHS Foundation Trust | N/A |
| Withdrawn | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors NCT04791228 | Children's National Research Institute | Phase 2 |
| Recruiting | Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) NCT05384821 | Centre Oscar Lambret | Phase 1 / Phase 2 |
| Recruiting | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors NCT05302921 | Children's National Research Institute | Phase 2 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton B NCT04968990 | St. Jude Children's Research Hospital | Phase 2 |
| Active Not Recruiting | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid NCT04377932 | Baylor College of Medicine | Phase 1 |
| Completed | Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma NCT06190574 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Active Not Recruiting | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid NCT05103631 | Baylor College of Medicine | Phase 1 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence NCT04758455 | Mansoura University | N/A |
| Unknown | Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Childre NCT05179850 | West China Hospital | — |
| Completed | Drug Sensitivity and Mutation Profiling NCT04956198 | Florida International University | — |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778 | Seattle Children's Hospital | Phase 1 |
| Unknown | Study of Wilms Tumors Among Patients of Shefa Al-Orman Children Cancer Hospital NCT06288802 | South Egypt Cancer Institute | — |
| Completed | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma NCT04040231 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Pencil Beam Scanning in Patients With Renal Tumors NCT03810651 | Children's Hospital of Philadelphia | EARLY_Phase 1 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies NCT04308330 | New York Medical College | Phase 1 |
| Terminated | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms T NCT02581384 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | International PPB/DICER1 Registry NCT03382158 | Children's Hospitals and Clinics of Minnesota | — |
| Completed | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors NCT02982941 | MacroGenics | Phase 1 |
| Terminated | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumor NCT02536183 | AeRang Kim | Phase 1 |
| Completed | Impact of an Orthotic Intervention in Children With Peripheral Neuropathy NCT03655587 | Children's Hospitals and Clinics of Minnesota | N/A |
| Withdrawn | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors NCT02689336 | Washington University School of Medicine | Phase 2 |
| Terminated | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) NCT02624388 | University of Virginia | Phase 2 |
| Completed | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma NCT02452554 | Children's Oncology Group | Phase 2 |
| Completed | Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia NCT02714790 | A.O.U. Città della Salute e della Scienza | — |
| Completed | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors NCT02390843 | Emory University | Phase 1 |
| Terminated | ODSH + ICE Chemotherapy in Pediatric Solid Tumors NCT02164097 | New York Medical College | Phase 1 |
| Completed | Molecular-Guided Therapy for Childhood Cancer NCT02162732 | Giselle Sholler | N/A |
| Completed | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors NCT02076906 | AeRang Kim | Phase 1 |
| Completed | Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors NCT01661400 | Washington University School of Medicine | Phase 1 |
| Completed | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory S NCT01625351 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | iCAT for Recurrent/Refractory/HR Solid Tumors NCT01853345 | Dana-Farber Cancer Institute | — |
| Completed | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors NCT01331135 | Emory University | Phase 1 |
| Completed | Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases NCT01252901 | Universitätsklinikum Hamburg-Eppendorf | — |
| Completed | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory C NCT01222780 | Acrotech Biopharma Inc. | Phase 1 |
| Withdrawn | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors NCT01130623 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pharmacokinetic Study of Doxorubicin in Children With Cancer NCT01095926 | University Hospital Muenster | Phase 2 |
| Completed | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors NCT00931931 | Timothy Cripe | Phase 1 |
| Completed | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer NCT00436657 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transpl NCT00336531 | Samsung Medical Center | Phase 4 |
| Active Not Recruiting | Study of Kidney Tumors in Younger Patients NCT00898365 | Children's Oncology Group | — |
| Completed | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome NCT00565903 | Ashley Hill | — |
| Completed | Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphom NCT00152126 | St. Jude Children's Research Hospital | N/A |
| Completed | A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor NCT00187031 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric P NCT00011414 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies NCT00038207 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers NCT00141765 | University of Michigan Rogel Cancer Center | Phase 2 |
| Unknown | Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anom NCT00503893 | M.D. Anderson Cancer Center | — |